ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025
Annexin A2 Contributes to Release of Extracellular Vimentin in Response to Inflammation.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The role of Annexin A2 in Alzheimer's disease: From cellular functions to therapeutic potential.The FEBS journal · 2026Review
- VSTM2L mediates the release of extracellular vimentin to drive lymph node metastasis in gastric cancer.Biology direct · 2026Article
- IID 2025: Physical protein interaction data with detection types, co-purified protein sets, molecular docking, and immune cell networks.Nucleic acids research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Vimentin, an abundant intracellular cytoskeletal protein, is secreted into the extracellular space, where it can amplify tissue destruction in inflammatory diseases. The mechanisms by which inflammation promotes the release of extracellular vimentin (ECV) are not defined. In human subjects, we found > twofold higher levels of ECV in gingival crevicular fluid from periodontitis sites with inflammation compared with healthy sites. In cultures of human gingival fibroblasts (hGFs) treated with 1% serum or IL-1β (10 ng/mL) to model tissue injury or inflammation, respectively, we found that 1% serum increased ECV release > 11-fold while IL-1β further enhanced release 17-fold. Mass spectrometry of vimentin immunoprecipitates identified Annexin A2 (AnxA2), a Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.